CMS Adds Veltassa to CY16 Formulary Reference File; H.C. Wainwright Affirms Relypsa (RLYP) at 'Buy'

Go back to CMS Adds Veltassa to CY16 Formulary Reference File; H.C. Wainwright Affirms Relypsa (RLYP) at 'Buy'

Relypsa (RLYP) Veltassa 'Off To A Strong Start' - Spherix Global Insights

February 11, 2016 11:33 AM EST

Spherix Global Insights said a recent study with 101 US nephrologists in late January 2016 showed "promising activity" for Relypsa's (NASDAQ: RLYP) Veltassa.

Prior to launch, but following the October approval, unaided awareness of Veltassa was high which likely paved the way for early trial. In addition to the 20% of surveyed nephrologists... More